Boston Scientific Co. (BSX) Stake Lessened by Standard Life Aberdeen plc

Standard Life Aberdeen plc lowered its position in Boston Scientific Co. (NYSE:BSX) by 0.8% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 12,579,734 shares of the medical equipment provider’s stock after selling 102,367 shares during the period. Standard Life Aberdeen plc owned approximately 0.92% of Boston Scientific worth $311,914,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Greenwood Capital Associates LLC boosted its position in Boston Scientific by 71.7% in the 3rd quarter. Greenwood Capital Associates LLC now owns 91,579 shares of the medical equipment provider’s stock worth $2,671,000 after purchasing an additional 38,249 shares in the last quarter. Knights of Columbus Asset Advisors LLC increased its stake in shares of Boston Scientific by 94.9% in the 3rd quarter. Knights of Columbus Asset Advisors LLC now owns 38,600 shares of the medical equipment provider’s stock worth $1,126,000 after acquiring an additional 18,800 shares during the last quarter. LS Investment Advisors LLC increased its stake in shares of Boston Scientific by 5.8% in the 3rd quarter. LS Investment Advisors LLC now owns 40,621 shares of the medical equipment provider’s stock worth $1,185,000 after acquiring an additional 2,209 shares during the last quarter. Chevy Chase Trust Holdings Inc. increased its stake in shares of Boston Scientific by 1.4% in the 3rd quarter. Chevy Chase Trust Holdings Inc. now owns 1,197,587 shares of the medical equipment provider’s stock worth $34,934,000 after acquiring an additional 16,992 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Boston Scientific by 3.6% in the 3rd quarter. Legal & General Group Plc now owns 6,760,998 shares of the medical equipment provider’s stock worth $197,195,000 after acquiring an additional 232,309 shares during the last quarter. Hedge funds and other institutional investors own 87.77% of the company’s stock.

Shares of Boston Scientific Co. (NYSE BSX) traded up $0.19 during trading on Wednesday, reaching $27.02. The company had a trading volume of 344,836 shares, compared to its average volume of 9,277,882. Boston Scientific Co. has a 12 month low of $23.29 and a 12 month high of $29.93. The stock has a market cap of $37,350.93, a PE ratio of 383.29, a price-to-earnings-growth ratio of 1.97 and a beta of 0.81. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58.

Boston Scientific (NYSE:BSX) last announced its earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, meeting analysts’ consensus estimates of $0.34. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The company had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.39 billion. During the same period last year, the business posted $0.30 EPS. Boston Scientific’s revenue for the quarter was up 9.9% on a year-over-year basis. equities research analysts anticipate that Boston Scientific Co. will post 1.37 EPS for the current year.

A number of analysts have issued reports on BSX shares. TheStreet raised Boston Scientific from a “c+” rating to a “b” rating in a research note on Thursday, January 18th. BMO Capital Markets reissued a “buy” rating and set a $31.00 price objective on shares of Boston Scientific in a research report on Wednesday, November 29th. JPMorgan Chase & Co. reissued a “buy” rating on shares of Boston Scientific in a research report on Wednesday, November 29th. Canaccord Genuity cut their price objective on Boston Scientific from $36.00 to $35.00 and set a “buy” rating for the company in a research report on Wednesday, November 29th. Finally, Royal Bank of Canada reissued a “buy” rating and set a $31.00 price objective on shares of Boston Scientific in a research report on Tuesday, November 7th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $31.00.

In other news, EVP Michael P. Phalen sold 15,500 shares of Boston Scientific stock in a transaction dated Wednesday, November 29th. The stock was sold at an average price of $26.66, for a total value of $413,230.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP David A. Pierce sold 5,152 shares of Boston Scientific stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $27.00, for a total value of $139,104.00. Following the completion of the transaction, the senior vice president now owns 38,116 shares of the company’s stock, valued at approximately $1,029,132. The disclosure for this sale can be found here. Insiders sold a total of 177,032 shares of company stock valued at $4,648,733 in the last quarter. Company insiders own 0.74% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/21/boston-scientific-co-bsx-stake-lessened-by-standard-life-aberdeen-plc.html.

Boston Scientific Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply